What Happened: Left was a central player in the short squeeze of GameStop shares back in 2021. The Citron Research founder told Benzinga that he went short GameStop shares this week. "Of course ...

Citron Research, known for its anti-crypto stance, has been hit with a fine from the US Securities and Exchange Commission. Andrew Left, founder and executive editor of Citron Research ...

Fresh accusations by federal authorities that one of the industry’s most prominent players, Andrew ... his firm, Citron, and send him to prison for years. According to the SEC, Left generated ...

GameStop Short Seller And Citron Founder Andrew Left Pleads Not Guilty To Fraud Charges Short Seller Andrew Left Turns Himself In On Securities Fraud Charges: Report GameStop Short Seller And ...

Bitcoin bull Andrew Left's Citron Research has called for a reigning-in of recent Bitcoin sentiment, placing a short bet against the "overheated" MSTR stock of Bitcoin-holding firm MicroStrategy.

MicroStrategy Inc shares tumbled after Andrew Left’s Citron Research said in a post on X that it’s betting against the software company, which has effectively transformed itself into a Bitcoin ...

Andrew Left, a short seller whose targets have included Valeant and Mobileye, released a report saying he has identified another short and the company's stock is tanking. Left, the founder of ...

WASHINGTON, Oct 22 (Reuters) - Ryan Choi, an associate of U.S. short seller Andrew Left of Citron Research, agreed to pay $1.8 million to settle U.S. Securities and Exchange Commission (SEC ...

Shares of Root jumped as high as 19.7% Friday morning as Citron's Andrew Left published a report saying the highly-shorted auto-insurance company is "a misunderstood short." "This is a disruptive ...

(Bloomberg) -- An investment adviser who helped short seller Andrew Left found his embattled Citron Research firm was sued by the US Securities and Exchange Commission for allegedly assisting in the ...

According to Left’s website, more than 50 companies that have been investigated by his firm, Citron Research, have become the targets of regulatory intervention.